A low-dose cream, tablet or ring that many postmenopausal women have never heard of is now associated with something more consequential than comfort. New analysis links vaginal estrogen prescriptions in women with recurrent urinary tract infections to lower rates of sepsis, hospitalization and death over the following years.
The finding, published in the journal Urology and reported by CIDRAP, draws on a large real-world database of electronic health records rather than a clinical trial. That distinction matters and is addressed below.
The immediate household relevance is this: recurrent UTIs are common after menopause, they are expensive, and they are the one symptom group least likely to result in a vaginal estrogen prescription, according to Medicare data. That gap is the story.
Local Estrogen Is Not the Same as Hormone Pills
The distinction between local and systemic therapy is the single most important thing for a reader to get right, and it is routinely blurred.
Systemic menopausal hormone therapy, taken as a pill or patch, circulates through the body and carries a different risk conversation. Low-dose vaginal estrogen is applied locally and is minimally absorbed into the bloodstream. It is used for the vulvar, vaginal and urinary symptoms grouped under genitourinary syndrome of menopause, or GSM.
Stephanie Faubion, MD, director of the Mayo Clinic Center for Women's Health and medical director of the Menopause Society, described the underlying tissue change plainly: "When you lose estrogen, tissues become thinner, less elastic, have less blood flow." The lower urinary tract thins along with the vaginal tissue, and vaginal pH rises.
That pH shift matters because it makes it harder for protective lactobacilli to survive. Their decline is associated with a higher risk of urinary infection. Local estrogen appears to reverse part of that change, which is the proposed mechanism behind the infection findings.
Unlike hot flashes, which fade over time, GSM tends to worsen with age rather than resolve on its own.
What the New Analysis Found
The Urology paper analyzed records from the Epic Cosmos database, drawing on electronic health records across multiple U.S. health systems. It compared women with recurrent urinary tract infections who received a vaginal estrogen prescription against those who did not, following outcomes over eight years.
Women who were prescribed vaginal estrogen had lower rates of sepsis, hospitalization and death. An earlier version of the work, presented at the American Urological Association annual meeting, reported the biggest and most consistent differences in women older than 55.
Recurrent UTI is generally defined as two infections within six months or three or more within a year. The clinical stakes are not trivial. Urinary infections can ascend to the kidneys and progress to sepsis, which is why hospitalization drives so much of the cost associated with complicated cases.
The 2025 AUA, CUA and SUFU guideline amendment on recurrent uncomplicated UTIs continues to recommend offering vaginal estrogen to perimenopausal and postmenopausal women with recurrent infections when there is no contraindication. The new analysis strengthens the case behind an existing recommendation rather than creating a new one.
What the Evidence Does Not Prove
This is observational research. Women who receive a prescription may differ from women who do not in ways records cannot capture, including overall health, engagement with care and access to a specialist.
That concern is not hypothetical here. The Medicare data described below show that healthier women and women with fewer comorbidities were more likely to fill a vaginal estrogen prescription. If healthier women are more likely to be treated, some of the difference in sepsis and death rates could reflect who got the prescription rather than what the prescription did.
There are also limits on long-term safety data. The JAMA Network Open authors noted that most vaginal estrogen trials evaluate only a 12-week course, even though GSM is progressive and requires long-term management, and that safety evidence beyond one year remains limited.
No randomized trial has been powered to determine whether vaginal estrogen affects heart disease, cancer or blood clots. Observational data from the Women's Health Initiative found no association between vaginal estrogen use and increased risk of stroke, cancer or venous thromboembolism.
Why Most Women Who Might Benefit Never Fill a Prescription
A Medicare cohort study published in JAMA Network Open examined 1,838,732 women aged 66 and older with a diagnosis indicative of GSM. Only 9.0% filled a vaginal estrogen prescription, at a median of 15 months after diagnosis.
The pattern within that number is the striking part. Women whose only GSM-related diagnosis was recurrent UTI were the least likely of any group to fill a prescription, with a fill rate of 1.4% and adjusted odds roughly half those of women with local sexual symptoms.
Uptake also varied by age, health status and race. Women aged 86 and older had adjusted odds of about 0.59 compared with women aged 66 to 70. Women with the highest comorbidity scores were less likely to fill a prescription than the healthiest women. Black beneficiaries had adjusted odds of 0.60 compared with non-Hispanic White beneficiaries.
Part of the explanation is labeling history. Until recently, all estrogen-containing products carried a boxed warning describing risks including heart disease, breast cancer and dementia. The FDA approved labeling changes removing those specific boxed-warning statements from six menopausal hormone therapy products, including a topical vaginal estrogen product, after initiating the change in November 2025. Twenty-nine drug companies submitted proposed labeling revisions.
FDA Commissioner Marty Makary, MD, MPH, framed the action around information rather than promotion, noting that "women face symptoms of menopause that can last for years." The Menopause Society supported removing the boxed warning from low-dose vaginal products specifically, while noting that systemic estrogen still carries risks that warrant individual discussion.
What to Ask a Clinician and What Comes Next
Nobody should start, stop or change hormone therapy based on a news article. For women having repeated urinary infections after menopause, the reasonable step is to raise the topic at the next appointment rather than wait for it to be offered.
Useful questions include whether GSM could be contributing to repeat infections, whether local vaginal estrogen is appropriate given personal medical history, and how cream, tablet and ring formulations differ in cost and convenience. Creams accounted for about 90% of prescriptions in the Medicare analysis, though trial evidence suggests many patients prefer rings or tablets.
Cost is a real barrier and worth naming directly. Coverage varies between Medicare Part D plans, Medicare Advantage plans and commercial insurance, and generic options may be available. Patients facing a denial can ask a prescriber about prior authorization, appeals, alternative formulations and manufacturer assistance programs.
Faubion has argued that this belongs in primary care rather than only in gynecology, since internal and family medicine physicians see these patients routinely. Whether prescribing patterns shift now that the boxed warning language has changed is the open question, and one that will take another round of utilization data to answer.
Anyone with fever, back or flank pain, confusion, or a urinary infection that is rapidly worsening should seek urgent medical care, since those can be signs the infection is spreading.
Frequently Asked Questions
What did the new analysis find? In a large electronic health record database, women with recurrent urinary tract infections who were prescribed vaginal estrogen had lower rates of sepsis, hospitalization and death over eight years than those who were not.
Does this prove vaginal estrogen prevents those outcomes? No. The study is observational. Women who receive prescriptions may be healthier overall, which could explain part of the difference.
How is vaginal estrogen different from hormone pills? Vaginal estrogen is applied locally at a low dose and is minimally absorbed into the bloodstream. Systemic hormone therapy circulates through the body and carries a different risk profile.
Why do UTIs become more common after menopause? Declining estrogen thins vaginal and lower urinary tract tissue and raises vaginal pH, which reduces protective lactobacilli and makes infection more likely.
Did the FDA change the warning label? Yes. The FDA approved labeling changes to six menopausal hormone therapy products, including a topical vaginal estrogen product, removing boxed-warning statements on cardiovascular disease, breast cancer and probable dementia.
How many older women with symptoms actually use it? In a Medicare cohort of more than 1.8 million women aged 66 and older with a GSM-related diagnosis, 9.0% filled a vaginal estrogen prescription. Among those whose only diagnosis was recurrent UTI, the rate was 1.4%.
When should someone seek urgent care? Fever, back or flank pain, confusion or a rapidly worsening urinary infection can indicate the infection is spreading and require prompt medical evaluation.
